{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:24:47Z","timestamp":1775237087069,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["941426"],"award-info":[{"award-number":["941426"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.intimp.2021.107833","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T09:07:44Z","timestamp":1627895264000},"page":"107833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model"],"prefix":"10.1016","volume":"98","author":[{"given":"Mona","family":"Yazdani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin Reza","family":"Nikpoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nema","family":"Mohamadian Roshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Seifalian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Badiee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2021.107833_b0005","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nri1592","article-title":"Dendritic cells as therapeutic vaccines against cancer","volume":"5","author":"Banchereau","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107833_b0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"6230","key":"10.1016\/j.intimp.2021.107833_b0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.intimp.2021.107833_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020092","article-title":"Therapeutic cancer vaccination with ex vivo RNA-transfected dendritic cells-an update","volume":"12","author":"Dorrie","year":"2020","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.intimp.2021.107833_b0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","article-title":"Towards superior dendritic-cell vaccines for cancer therapy","volume":"2","author":"Saxena","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"8","key":"10.1016\/j.intimp.2021.107833_b0030","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic cell-based immunotherapy: state of the art and beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2021.107833_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030590","article-title":"Dendritic cells in anticancer vaccination: rationale for ex vivo loading or in vivo targeting","volume":"12","author":"Baldin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.intimp.2021.107833_b0040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/atm.2017.06.13","article-title":"Dendritic cell therapy in melanoma","volume":"5","author":"Alvarez-Dominguez","year":"2017","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.intimp.2021.107833_b0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.intimp.2021.107833_b0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cellimm.2010.09.003","article-title":"Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response","volume":"266","author":"Eisenberg","year":"2010","journal-title":"Cell Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2021.107833_b0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/vaccines3030662","article-title":"Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy","volume":"3","author":"Fan","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2021.107833_b0060","doi-asserted-by":"crossref","first-page":"27206","DOI":"10.1038\/srep27206","article-title":"A lipid based antigen delivery system efficiently facilitates MHC class-I antigen presentation in dendritic cells to stimulate CD8(+) T cells","volume":"6","author":"Maji","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2021.107833_b0065","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2019-0173","article-title":"Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems","author":"Yazdani","year":"2020","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.intimp.2021.107833_b0070","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1020151025412","article-title":"Liposomal delivery of CTL epitopes to dendritic cells","volume":"22","author":"Chikh","year":"2002","journal-title":"Biosci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2021.107833_b0075","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.4049\/jimmunol.1801634","article-title":"Antigen priming with enantiospecific cationic lipid nanoparticles induces potent anti-tumor CTL responses through novel induction of a type I IFN response","volume":"202","author":"Gandhapudi","year":"2019","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107833_b0080","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/jcmm.13343","article-title":"Enhanced immune response induced by P5 HER2\/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine","volume":"22","author":"Gholizadeh","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"13","key":"10.1016\/j.intimp.2021.107833_b0085","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/bioinformatics\/btu059","article-title":"Induction of T-cell memory by a dendritic cell vaccine: a computational model","volume":"30","author":"Pappalardo","year":"2014","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.intimp.2021.107833_b0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"BBA"},{"issue":"2","key":"10.1016\/j.intimp.2021.107833_b0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/iep.12114","article-title":"Behaviour of four different B16 murine melanoma cell sublines: C57BL\/6J skin","volume":"96","author":"Danciu","year":"2015","journal-title":"Int. J. Exp. Pathol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107833_b0100","doi-asserted-by":"crossref","first-page":"e1397250","DOI":"10.1080\/2162402X.2017.1397250","article-title":"Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models","volume":"7","author":"Fotaki","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2021.107833_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"22 Pt 1","key":"10.1016\/j.intimp.2021.107833_b0110","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2021.107833_b0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nri2173","article-title":"Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting","volume":"7","author":"Tacken","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107833_b0120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00262-007-0390-4","article-title":"A simple but effective cancer vaccine consisting of an antigen and a cationic lipid","volume":"57","author":"Chen","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"1 Pt A","key":"10.1016\/j.intimp.2021.107833_b0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.imlet.2014.07.008","article-title":"Effective induction of anti-tumor immunity using p5 HER-2\/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN","volume":"162","author":"Mansourian","year":"2014","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.intimp.2021.107833_b0130","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1567201813666160712164149","article-title":"Stimulation of tumor-specific immunity by p5 HER-2\/neu generated peptide encapsulated in nano-liposomes with high phase transition temperature phospholipids","volume":"14","author":"Yazdani","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.intimp.2021.107833_b0135","article-title":"Preparation of nanoliposomes linked to HER2\/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer","author":"Rastakhiz","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2021.107833_b0140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/21691401.2019.1576702","article-title":"P435 HER2\/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer","volume":"47","author":"Farzad","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107833_b0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2010.03.027","article-title":"Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response","volume":"145","author":"Henriksen-Lacey","year":"2010","journal-title":"J. Control. Release"},{"issue":"15\u201316","key":"10.1016\/j.intimp.2021.107833_b0150","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.vaccine.2003.11.008","article-title":"Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition","volume":"22","author":"Foged","year":"2004","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.intimp.2021.107833_b0155","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20012100","article-title":"Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells","volume":"195","author":"Schuler-Thurner","year":"2002","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.107833_b0160","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/14760584.6.5.785","article-title":"Cationic liposomes as vaccine adjuvants","volume":"6","author":"Christensen","year":"2007","journal-title":"Expert Rev. Vacc."},{"issue":"5","key":"10.1016\/j.intimp.2021.107833_b0165","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/09687860600790537","article-title":"Immunostimulation of dendritic cells by cationic liposomes","volume":"23","author":"Vangasseri","year":"2006","journal-title":"Mol. Membr. Biol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107833_b0170","first-page":"1065","article-title":"Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy","volume":"23","author":"Yazdani","year":"2020","journal-title":"Iran J. Basic Med. Sci."},{"issue":"35","key":"10.1016\/j.intimp.2021.107833_b0175","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1016\/j.vaccine.2020.06.055","article-title":"Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma","volume":"38","author":"Yazdani","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2021.107833_b0180","doi-asserted-by":"crossref","first-page":"785634","DOI":"10.1155\/2015\/785634","article-title":"Pros and cons of antigen-presenting cell targeted tumor vaccines","volume":"2015","author":"Goyvaerts","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2021.107833_b0185","doi-asserted-by":"crossref","DOI":"10.5402\/2011\/497397","article-title":"The roles of CD4+ T cells in tumor immunity","volume":"2011","author":"Lai","year":"2011","journal-title":"ISRN Immunol."},{"key":"10.1016\/j.intimp.2021.107833_b0190","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2147\/IJN.S125866","article-title":"Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens","volume":"12","author":"Gao","year":"2017","journal-title":"Int. J. Nanomed."},{"issue":"7","key":"10.1016\/j.intimp.2021.107833_b0195","doi-asserted-by":"crossref","first-page":"e1328341","DOI":"10.1080\/2162402X.2017.1328341","article-title":"Trial watch: dendritic cell-based anticancer immunotherapy","volume":"6","author":"Garg","year":"2017","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.intimp.2021.107833_b0200","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2021.107833_b0205","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2021.107833_b0210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.nano.2010.12.010","article-title":"Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA","volume":"7","author":"Perche","year":"2011","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.intimp.2021.107833_b0215","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0960-894X(00)00251-1","article-title":"Synthesis and biological properties of new glycosidic cationic lipids for DNA delivery","volume":"10","author":"Bessodes","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.intimp.2021.107833_b0220","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1039\/c3bm60032g","article-title":"Sugar\/gadolinium-loaded gold nanoparticles for labelling and imaging cells by magnetic resonance imaging","volume":"1","author":"Irure","year":"2013","journal-title":"Biomater. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2021.107833_b0225","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/jm901295s","article-title":"Cationic amphiphile with shikimic acid headgroup shows more systemic promise than its mannosyl analogue as DNA vaccine carrier in dendritic cell based genetic immunization","volume":"53","author":"Srinivas","year":"2010","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.intimp.2021.107833_b0230","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1016\/j.biomaterials.2012.05.006","article-title":"A long-lasting dendritic cell DNA vaccination system using lysinylated amphiphiles with mannose-mimicking head-groups","volume":"33","author":"Srinivas","year":"2012","journal-title":"Biomaterials"},{"issue":"16","key":"10.1016\/j.intimp.2021.107833_b0235","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1039\/C8NR10293G","article-title":"Shikimoyl-ligand decorated gold nanoparticles for use in ex vivo engineered dendritic cell based DNA vaccination","volume":"11","author":"Meka","year":"2019","journal-title":"Nanoscale"},{"issue":"5","key":"10.1016\/j.intimp.2021.107833_b0240","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1440-1711.2005.01371.x","article-title":"Dendritic cell dysfunction in cancer: a mechanism for immunosuppression","volume":"83","author":"Pinzon-Charry","year":"2005","journal-title":"Immunol. Cell Biol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107833_b0245","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ymthe.2006.02.009","article-title":"Dendritic cell-based tumor vaccines and antigen presentation attenuators","volume":"13","author":"Evel-Kabler","year":"2006","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2021.107833_b0250","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.4049\/jimmunol.175.9.6169","article-title":"Tumor progression can occur despite the induction of very high levels of self\/tumor antigen-specific CD8+ T cells in patients with melanoma","volume":"175","author":"Rosenberg","year":"2005","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107833_b0255","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1074-7613(04)00108-6","article-title":"Autoimmunity through cytokine-induced dendritic cell activation","volume":"20","author":"Banchereau","year":"2004","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2021.107833_b0260","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107833_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:24:43Z","timestamp":1747308283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921004690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":53,"alternative-id":["S1567576921004690"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107833","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107833"}}